Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical ...

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

Pulnovo Medical announced the enrollment of the first two U.S. patients in the PULSE-LHD IDE clinical trial of Pulmonary Artery Denervation (PADN) for pulmonary hypertension associated with left heart disease. The study, supported by FDA IDE and CMS Category B coverage, aims to evaluate PADN as a potential treatment where no therapies currently exist.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You now have a clear path to build products that address pulmonary hypertension linked to left heart disease in the US. The FDA’s IDE and CMS coverage open crucial market access to a previously untreatable patient group.

◆ Coverage

1 source · 24 Aug 2026

◆ Related on Wire

◆ Topics

Medtechclinical-trialpulmonary-hypertensionFDA-IDEmedical-deviceCMS-coveragePADN